NCT00048217Unknown1 期
A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102
适应症
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- Trimeris
- 试验地点
- 2
研究概览
简要总结
Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Completion T1249-102;
- •Currently failing a T-20 containing regimen
排除标准
- •Non-completion of T1249-102.
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
A Rollover Study of CC-122Non-Hodgkin LymphomaNCT05688475Bristol-Myers Squibb12
已完成
2 期
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its SafetyCancerNCT04125693Bayer1
已完成
3 期
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial HypertensionHypertension, PulmonaryNCT00863681Bayer396
Enrolling By Invitation
不适用
RACE 2: a Long Term Follow-up of Patients Participating in the RACE TrialSevere Aplastic AnemiaNCT05049668European Society for Blood and Marrow Transplantation197
已完成
3 期
Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's DiseaseParkinson's DiseaseNCT00203138Teva Branded Pharmaceutical Products R&D, Inc.306